Hope Biosciences Receives Second FDA Clearance for a Phase II Clinical Trial for Protection Against COVID-19 – The Baytown Sun


Hope Biosciences, a clinical stage biotechnology company focused on developing cell-based therapeutics for acute and chronic disease, today announced that FDA has approved a Phase II clinical trial evaluating the safety and efficacy of Hope Biosciences’ allogeneic, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COVID-19.

During this pandemic, there are currently no approved therapies available to support immunity against the Coronavirus disease. Hope Biosciences’ proprietary core technology delivers high-quality, fully characterized, fresh mesenchymal stem cells, on-demand. MSCs are well-known for their immunomodulatory and regenerative potential. In a recent Phase I/II clinical trial for Rheumatoid Arthritis, results appeared to show that HB-adMSCs were safe and effective in attenuating systemic inflammation. “It is our expectation that providing HB-adMSC therapy will boost the immune system, especially in cases of individuals at high-risk